These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15272577)

  • 1. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor markers in urologic cancer.
    Javadpour N
    Urology; 1980 Aug; 16(2):127-36. PubMed ID: 6157242
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tumor markers in urological malignancies].
    Kuriyama M
    Nihon Rinsho; 1996 Jun; 54(6):1631-6. PubMed ID: 8691621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour markers in urology: aids in cancer diagnosis and management.
    Wahren B
    Urol Res; 1979 Jun; 7(2):57-67. PubMed ID: 89748
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and cellular biologic tumor markers in patients with urologic cancer.
    Javadpour N
    Hum Pathol; 1979 Sep; 10(5):557-68. PubMed ID: 93569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review.
    Nicholson BD; Jones NR; Protheroe A; Joseph J; Roberts NW; Van den Bruel A; Fanshawe TR
    Cancer Epidemiol; 2019 Apr; 59():15-21. PubMed ID: 30658216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor marker in urology].
    Shimazaki J; Ito H; Miyauchi T; Maruoka M; Isaka S; Masukagami T; Ando K
    Gan No Rinsho; 1983 May; 29(6):684-92. PubMed ID: 6192269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metastasis and markers].
    Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
    Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers of urinary tract carcinoma].
    Kikuchi H
    Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
    Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
    Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
    Neumann A; Keller T; Jocham D; Doehn C
    Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of radioimmunoanalysis for tumor markers in the diagnosis of carcinoma of the testes and prostate].
    Kausitz J
    Bratisl Lek Listy; 1988 Oct; 89(10):715-24. PubMed ID: 2463063
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"?
    Netto GJ
    Adv Anat Pathol; 2013 May; 20(3):175-203. PubMed ID: 23574774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
    Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
    APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next revolution in molecular theranostics: personalized medicine for urologic cancers.
    Aoun F; Kourie HR; Artigas C; Roumeguère T
    Future Oncol; 2015; 11(15):2205-19. PubMed ID: 26235183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.